275.26
+5.33(+1.97%)
Currency In USD
| Previous Close | 269.93 |
| Open | 268.05 |
| Day High | 279.15 |
| Day Low | 265.2 |
| 52-Week High | 377.46 |
| 52-Week Low | 200.63 |
| Volume | 321,445 |
| Average Volume | 357,271 |
| Market Cap | 6.11B |
| PE | -15.47 |
| EPS | -17.79 |
| Moving Average 50 Days | 308.99 |
| Moving Average 200 Days | 293.08 |
| Change | 5.33 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $3,607.6 as of June 01, 2025 at a share price of $275.26. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $2,427.77 as of June 01, 2025 at a share price of $275.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
GlobeNewswire Inc.
May 10, 2025 11:15 AM GMT
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced s
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
GlobeNewswire Inc.
Apr 18, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today t